Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Addex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
SEC filings, financial facts, source resources, and Goglides workspace context for American Assets Trust, Inc..
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenAcumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.
OpenOfficial-source baseline for American Assets Trust using SEC submissions, SEC XBRL companyfacts, FY2025 10-K, Q1 FY2026 10-Q, company-filed earnings materials, supplemental materials, proxy, credit facility filings, governance filings, and peer filings.
OpenTag facets appear after tag usage counts are rebuilt.